Tumor Rebiopsy During Progression Under Immunotherapy for Patients With Lung Cancer
Recruiting now · Not applicable
Conditions studied: Lung Cancer
In brief
The objective of the study aims to collect tumor tissue at the moment of progression under Immune checkpoint inhibitors (ICI) in biological resources center in Ambroise Paré hospital, in order to insure later study on molecular mechanism involving the progression of NSCLC and SCLC under ICI. The further analysis of research will be performed in the EA 4340 unity, Biomarkers and Clinical Trials in cancerology and onco-hematology, UVSQ, University of Paris-Saclay.
Key facts
- Study ID
- NCT04300062
- Run by
- Assistance Publique - Hôpitaux de Paris
- People needed
- 50
- Starts
- 2020-08-18
- Expected to finish
- 2027-08-01
- Last updated by the study team
- 2025-09-03
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Diagnosed NSCLC or SCLC;
- Patient treated priorly by ICI and progressed under ICI;
- Have provided written informed consent for the study;
- Be >/= 18 years of age on day of signing informed consent.
You may not qualify if…
- Patient under guardianship or curatorship;
- Unable to provide written informed consent for the study;
- Technical impossibility to carry out tissular rebiopsy under local anesthesia.
Where it is running
- Service de Pneumologie et Oncologie thoracique, Hôpital Ambroise Paré, APHP — Boulogne-Billancourt, France (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.